Epix COO resigns

Epix Medical president and COO Dr. Stephen Knight has left the Cambridge, MA-based company to become president of Fidelity Investments unit Fidelity Biosciences Group.

Knight will remain with the company, however, through Epix’s new drug application (NDA) submission for MS-325, an MR angiography contrast agent. CEO Michael Webb will add the role of president to his duties.

In other Epix news, the company reported positive results from phase II trials of MS-325. The agent was well-tolerated by patients with varying degrees of renal impairment, including those requiring dialysis, and had no adverse effect on renal function, Epix said.

By AuntMinnie.com staff writers
November 11, 2003

Related Reading

Epix continues to build revenues, trim losses in Q3, October 24, 2003

Epix to present phase III results, September 15, 2003

Epix exercises overallotment option, August 27, 2003

Epix sets share price, August 7, 2003

Epix to offer more shares, July 28, 2003

Copyright © 2003 AuntMinnie.com

Page 1 of 606
Next Page